Second annual Regenerative Medicine summit proves big win for The Bahamas – EyeWitness News

Nassau, The Bahamas The best and brightest global recently gathered in The Bahamas to discuss ways of making stem cell and regenerative health technologies available, accessible and affordable to everyone, everywhere.

Dr. Desiree Cox, Rhodes Scholar and Founder and CEO of HEALinc reflects, This event promotes research and innovation in medical technologies with the potential to help people stay healthy through their lifespan. Our presenters and sponsors delivered an immersive experience that bridged the gaps between modern regenerative medicine technologies and ancient healing arts of creativity, music, movement and breathwork.

The second annual HEALinc Future Health and Innovation Summit was hosted at the Grand Hyatt, Baha Mar Convention Center from October 2 4, 2019 with an audience of more than 200-participants. A slate of more than 50 presenters delivered thought-provoking presentations and the celebrity keynote speech was given by Dr. Joe Dispenza,an international lecturer, researcher and author who has been invited to speak in more than 33 countries on six continents. Dr. Dispenza challenged the audience to rewire the brains and recondition their bodies to make lasting life changes.

Dr. Steven Greco, Chief Scientific Officer of the Houston Healthspan Innovation Group said, Regenerative medicine and immune restoration treatments provide safe, accessible options for patients. Houston Healthspan was pleased to share some of the exciting pilot data related to orthopedic and neurological treatments delivered at Okyanos. Through our participation and the sponsorship of the Bosarge Family Foundation, we were able to collaborate on this Summit because of our shared commitment to HEALinc., and to The Bahamas.

Dr. Joshua Hare, Professor of Medicine at University of Miami and Co-founder and Chief Scientific Officer of Longeveron, presented important scientific data from Longeverons multiple FDA authorized stem cell trials in the US as well as the 60+ patients treated in The Bahamas in Longeverons approved open Registry for aging and musculoskeletal related disorders.Dr. Todd McAllister, CEO of Fountain Therapeutics scheduled to begin operations in Bimini was a keynote speaker at the Summit along with Dr. Robert Hariri, Founder and President of Celularity, and one of the angel investors of Fountain Therapeutics along with Peter Diamandis and Tony Robbins. Dr. Hariri says, This Summit is an ideal environment to engage in conversations that affirm our commitment to harnessing the powerful biology of the placenta to treat cancer, immunological and degenerative diseases and we commend Dr. Cox for her leadership in this regard.

Dr. Cox says, As we grow, we anticipate hosting events in the United States that provide a space for more individuals to showcase products and services that will allow more persons to live longer, healthier and happier lives because of the integration of modern and ancient regenerative health technologies.

The rest is here:
Second annual Regenerative Medicine summit proves big win for The Bahamas - EyeWitness News

Ridgefield woman, her mother write book about battle with MS – The Columbian

It hurt Margaret Godfrey to see daughter Rachel Carter in pain, so she painted.

And once the worst pain had passed, Carter needed a way to move forward, so she wrote.

In 2000, at age 24, Carter was diagnosed with multiple sclerosis, a disease where the immune system eats away at the lining of nerves and impairs or disables the brain and central nervous system.

Carter is now a married 43-year-old mother of three who lives in Ridgefield. But when she was diagnosed with MS, it marked a significant shift in her life. The woman who ran marathons, rode a motorcycle to high school and was once a deckhand on a small riverboat cruise ship to prove a point because she was told a woman couldnt hold that job, slowly morphed as her disease altered life.

It started with a fall on vacation during a run. Then falling on runs became more frequent. Gone went the marathons. In came the treadmill. Slowly, over the course of 12 years, the MS progressed and symptoms became debilitating. Running left completely. Neuropathic pain caused her to feel like she was sunburned in the morning, and by the afternoon or evening it felt like third degree burns. Carter left her job in sales in 2013.

I would always end up in tears in the bed, Carter said.

Carter has chronicled her battle with MS, and a stem cell treatment she credits with turning her prognosis around, in a new book called Enduring the Cure: My MS Journey to the Brink of Death and Back. Her mother helped her edit the book, and provided the books cover art. Adrienne van Der Valk also edited the book.

Through pain, Carter and her mother have created art. About five years ago, Carter underwent an experimental stem cell transplant in Seattle to help her rebuild her immune system. Carter lived in Seattle for about three months, while her parents watched two of her children, and the other child lived with an aunt.

As part of the procedure, Carters own stem cells were harvested and then reintroduced to her body after chemotherapy depleted most of her immune system. Its what she described as a rebooting of her whole immune system, in hopes that it would stop attacking her brain and spinal cord. Carter still has her previous brain damage, which impacts her memory and brain power; but so far, the stem cell transplant has improved her condition greatly, she said.

Carter has more energy she used to sometimes not be able to leave bed some days. She also can stand upright and walk easily she used to rely on a walker. And her pain is minimal now, the biggest improvement.

Carters family kept notes during her treatment, and Carter decided to use those, and the memories of her family, to help her write the book with van Der Valk.

Thinking was very fatiguing for Carter, since she still has the brain damage from MS. She could only work about one to two hours on the book at a time. She said writing was frustrating and hard in many ways. Parts of my brain are gone, Carter explained. She said it requires her about 10 times as much brain matter as the average person to process something simple.

Its so much pressure to have something you feel like you have to do, and then you cant do it. I had so little energy, Carter said. I cant explain very well because so many words dont come to me.

In spite of the challenges, Carter feels like sharing her experience will help others because, in life, we all have hard situations, she said.

Godfrey, a 70-year-old painter who lives in Blue River, Ore., found art in the familys experience. She drew inspiration from Gustav Klimt, an Austrian symbolist, who painted in the late 1800s and early 1900s, and created symbolic paintings of her daughter. Godfrey said art makes her an intellectual because of how she has to think about what shes painting. This time she was researching her own child.

Godfrey did a painting of Carter surrounded by old running shoes, a life she had to give up. She did a painting of Carter without her hair, which centered on Carters worries. She did a painting of Carter covered by a quilt with her three kids on it, what kept her going and allowed her to recover. She did a painting of Carter lying in a hospital bed, looking exhausted and resigned, which is the books cover. The final painting in the series, called The Journey Is Not Done, features Carter with hair, months after treatment. It has an unfinished mosaic because Carters journey isnt over.

Creating art is a very meditative thing, Godfrey said. Rather than getting wrapped up in emotions, once I start painting the world is me and paper. All the worries of life disappear. It was a way to enjoy that experience of just being able to throw out my expression, without getting too emotionally tangled up.

See more here:
Ridgefield woman, her mother write book about battle with MS - The Columbian

UK biotech startup Mogrify injects $16M to get novel cell therapies to market soon – TechCrunch

Cambridge, UK-based biotech startup Mogrify, which is working on systematizing the development of novel cell therapies in areas such as regenerative medicine, has closed an initial $16 million Series A.

The raise from investors Ahren Innovation Capital,Parkwalkand24Haymarketfollows a $4M seed in February taking its total raised to date to $20M.

Put simply, Mogrifys approach entails analysis of vast amounts of genomic data in order to identify the specific energetic changes needed to flip an adult cell from one type to another without having to reset it to a stem cell state with huge potential utility for a wide variety of therapeutic use-cases.

What were trying to do with Mogrify is systematize that process where you can say heres my source cell, heres my target cell, here are the differences between the networks and here are the most likely points of intervention that were going to have to make to drive the fate of an adult cell to another adult cell without going through a stem cell stage, says CEO and investor Dr Darrin Disley.

So far he says its successfully converted 15 cells out of 15 tries.

Were now rapidly moving those on through our own programs and partnership programs, he adds.

Mogrifys business has three main components: Internal program development of cell therapies (current cell therapies its developing include enhancing augmented cartilage implantation; non-invasive treatment of ocular damage; and for blood disorders). Its also developing a universal source of cells for use in immunotherapy to act as disease-eaters, asDisley puts it.

Speculative IP development is another focus. Because of the systematic nature of the technology were in a position very rapidly to identify areas of therapy that have particular cell conversions at their essence and then drive that IP generation around those cells very quickly and create an IP footprint, he says.

Partnering deals is the third piece. Mogrify is also working with others to co-develop and bring targeted cell therapies to market. Disley says its already closed some partnerships, though its not announcing any names yet.

The startup is drawing on around a decades worth of recent work genomics science. And specifically on a data-set generated by an international research effort, called Fantom 5, which its founders had early access to.

We started with that massive Fantom data-set. Thats the baseline, the background if you like. Think of it like two cities in America: Chicago and New York. Theres your source cell, theres your target cell. And because you have all the background data of every piece of the network every building, every skyscraper if you look at the two you can identify the difference in the gene expression, therefore you can identify which factors will regulate a wide array of those genes. So you can start identifying the differences between the two, explainsDisley.

Weve then added to that massive data sets in DNA-protein and protein-protein interactions so you start to now overlay all of that data. And then weve added on top of that new next-gen sequencing data and epigenetic data. So youve now got this massive data-set. Its like having a network map between all the different cell types. So youre therefore then able to make predictions on how many interventions, what interventions are needed to drive that change of state and its systematic. It doesnt just recommend one set. Theres a ranking. It can go down to hundreds. And there is some overlap and redundancies, so for example if one youre preferred thing doesnt work the way you wanted it to you can go back and select another.

Or if theres an IP issue around that factor you can ignore that piece of the network and use an alternative route. And once youve got to your target cell, if it needs to some tweaking you can actually re-sequence it and take that back and thats your starting cell again. And you can go through this optimization process. So what comes out at the other end youve got a patent that it like a small molecule composition of matter patent; its the therapeutic. So youre not coming out with the target, youre actually coming out with here is the composition of matter on the cell.

In terms of timeframe for getting novel cell therapies from concept to market Disley suggests a range of between four and seven years.

Once youve identified the cell type that can be be the basis of your GMP manufacturable process and then you can tweak that to take it to the therapeutic indication you can develop a cell therapy and bring that to market in five years, he says. Its not like the old days with small molecules where it can take ten, 15, 20 years to get a serious therapy on the market.

When youre treating patients is because there are no other treatments for them, when you go into phase two and do your safety study [and] efficacy study youre actually treating patients already in terms of their disease. And if you get it right you can get a fast track approval. Or a conditional approval so that you may not even have to do a phase 3 [testing].

Were not using any artificial intelligence here, he also emphasizes, pointing to his experience investing in companies in the big extreme data space which he argues do best by using unbiased approaches.

AI I think is still trying to find its way, he continues. Because in its essence it will be able to get to answers with smaller amounts of data but its only as good as the data you train it on. And the danger with AI it just learns to recognize what you want it to recognize. It doesnt know what it doesnt know.

In combination, once you continue to generate this massive cell network data etc you can start applying aspects of machine learning and AI. But you couldnt do Mogrify with AI without the data. You have to do it that way. And the data is so complex and combinatorial 2,000 transcription factors, in terms of regulation of those genes, they then interact in network to do the protein-protein interactions, youve got epigenetic aspects of that, you could even start adding cell microbiome effects to that later so youve got a lot of factors that could influence the phenotype of the cell thats coming out the other end.

So I think with AI you have to be a little careful. I think it will be a more optimizing tool once youve got sufficient confidence in your system.

The plan for the Series A funding is to ramp up Mogrifys corporate operations and headcount including bringing in senior executives and expertise from industry as well as spending to fund its therapy development programs.

Disley notes its recent appointment of Dr Jane Osbourn as chair as one example.

Were bringing in more people with a lot of cell therapy experience from big pharma, around then more on the manufacturing and delivery of that so really building so that were not just a tech company, he says. Weve very strong already, were already 35 people on the tech and early stage drug discovery side were going to add another 30 to that. But thats going to be increasingly more people with big pharma, cell therapy development, manufacturing experience to get products on to market.

Partner search is another focus for the Series A. Were trying to find the right strategy partners. Were not doing services, were not doing products so we want to find the right strategic partners in terms of doing multi-programs in a partnership, he adds. And then a series of more tactical deals where people have got a specific problem with a cell conversion. These more turnkey deals, if you like. We still get up-fronts, milestones and royalties but theyre smaller.

Despite now having enough money for the next two to two and half years its also leaving the Series A open to continue expanding the round over the next 12 months up to a maximum of another $16M.

We have so many interested investors, Disley tells us. This round we didnt actually open our round. We did it with internal investors and people were very close to who weve worked with before, and there were investors lining up [so] we are leaving it open so that in these next 12 months we may choose to increase the amount we bring in.

It would be a maximum of another $16M if it was an A round but we may decide just to go straight forward if we progress very fast to a much bigger B round.

See more here:
UK biotech startup Mogrify injects $16M to get novel cell therapies to market soon - TechCrunch

How the bodys cells can prevent the need for surgery – ABC 4

Posted: Oct 8, 2019 / 09:45 AM GMT-0600 / Updated: Oct 10, 2019 / 01:15 PM GMT-0600

Stem cell therapy is one of the most successful procedures ever for solving joint pain. Your own bodys cells are injected back into the area where healing is needed: back, neck, hip, shoulder, etc. The new cells signal to body the need for regeneration, which starts to take place.

The treatment is a one-and-done injection, no surgery. Regenerative Medicine of Utah successfully treats many with stem cell therapy. One patient, John Dunn, was scheduled for knee replacement because of bone on bone pain. Before surgery he received an injection. Three months later and regenerated tissue was found in his knee joint. Six months later his knee was even better than that.

In just four weeks John was out of pain, but the body wasnt done healing. The cells continue signaling to the body the need for healing. Its usual to allow 12 months for the regeneration process to complete and reach its limit.

Making sure youre a candidateis important. Not everyone needs it. Many patients that end up being a candidateinitially thought they werent eligible. To know if youre a candidate schedulea consultation.

Right now, at Regenerative Medicine ofUtah an evaluation is $49 for the first 25 callers to (800)453-0286.

This article contains sponsored content.

Originally posted here:
How the bodys cells can prevent the need for surgery - ABC 4

ReNeuron cell-based treatment hailed by leading non-profit group funding research into treatments for retinal degenerative diseases – Proactive…

Benjamin Yerxa, chief executive of the Foundation Fighting Blindness, said results from a recent clinical trial represented a major step forward for sufferers of a degenerative disease called retinitis pigmentosa

A leading non-profit group funding research into treatments for retinal degenerative diseases has hailed as major step forward a potential therapy developed by ().

The comments from Benjamin Yerxa, chief executive of the Foundation Fighting Blindness, followed the presentation of data from a phase I/IIa clinical study by trial investigator Pravin Dugel.

He has been working on ReNeurons human retinal progenitor (hRPC) stem cell line, which has shown early promiseimproving, or stabilising clarity of vision in people with the degenerative disease retinitis pigmentosa.

Dugel's address to the American Academy of Ophthalmology Annual Meeting in San Francisco was based on the latest results from the clinical assessment of the drug candidate, published on October 2.

After the presentation, Yerxa said: "We're excited by the progress of ReNeuron's hRPC therapy.

From the Foundation's perspective, any gain in vision, or even stabilisation, is a major step forward for patients with RP as currently it is a condition where progressive loss of vision leads to blindness."

Earlier this month ReNeuron said it had seen rapid and profound results in the first three patients of the second phase of clinical studies of its human retinal progenitor cells.

The phase IIa trials saw noticeable improvements in visual acuity as measured by the number of letters that could be read on a standard eye chart.

Six months after treatment there was a mean improvement of 18.5 letters per treated eye, with a mean improvement of 12 letters per treated eye after nine months, whereas inexorable disease progression is the norm for this disease.

With total of 22 patients now treated and the study still ongoing, ReNeuron said the efficacy in subsequent patients was seen but at a lower rate and magnitude, with improvement in visual acuity ranging from +5 to +11 letters in the treated eye three months after treatment.

I believe that we are seeing a clear signal of efficacy in this patient population where any gain in vision, let alone the levels seen in some of these patients, is so hard to come by and so very much appreciated," said Dr Pravin Dugel, managing partner at Retinal Consultants of Arizona and clinical professor at the Roski Eye Institute in Los Angeles.

See the article here:
ReNeuron cell-based treatment hailed by leading non-profit group funding research into treatments for retinal degenerative diseases - Proactive...

Gay Couple Adopt HIV-Positive Child After She Was Rejected By Ten Other Families – UNILAD

A gay couple have spoken out about the immediate connection they felt after adopting a HIV-positive child who had been rejected by 10 other families.

Damian Pighin, 42, and Ariel Vijarra, 39, were the first gay couple to get married in the north-eastern Argentine province of Santa Fe, and made the decision to expand their family in 2011.

The married couple, from Rosario, had several years of disappointment before receiving a call in 2014 about a newborn baby who was ready to be adopted.

The baby girl, who was born with HIV, was 28 days old when Damian and Ariel received the call and were informed 10 families had previously rejected her.

However, they did not hesitate to accept her into their family, with Ariel telling local media:

As soon as I saw her, I felt that she was part of my life. The connection was immediate. We held her in our arms, gave her the bottle and she looked at us with her eyes wide open without crying.

The little girl, who has been named Olivia, responded very well to her HIV treatment and she immediately started to gain weight. A couple of years ago, the family received brilliant news when tests showed the virus was no longer detectable in Olivia.

The family grew by one more in 2015, when a woman who heard about the couples story wanted them to adopt her baby girl. They did, and so Damian and Ariel welcomed Victoria into their lives.

The two siblings are similar in age, with Olivia turning five years old later this month and Victoria celebrating the same birthday in February.

Ariel and Damien work for non-governmental organisation Acunar Familias, which roughly translates to Cradle Families, helping couples adopt unwanted children.

Although there is currently no cure for HIV, medical treatment is available that significantly reduces the amount of the virus in the body. As per Medical News Today, this can be to the point the virus becomes undetectable in the blood.

An undetectable viral load means the person living with HIV is no longer infectious and the virus is no longer able to damage their immune system.

Earlier this year, a third person appeared to have been cured from the virus when they underwent a stem cell transplant to treat cancer, rather than HIV. The transplant involved killing most of their immune cells with radiotherapy or drugs, and then replacing them with cells from a donor.

Although this provides hope a cure is close to being confirmed, bone marrow transplants reportedly wont be used for people with HIV who dont have cancer because of the risks involved in the procedure namely graft versus host disease, infection, organ damage, and death.

Regardless, Doctor Annemarie Wensing, a virologist at the University Medical Center Utrecht, told The New York Times she hoped news of the cases will inspire a generation of doctors to keep striving for what was previously believed to be impossible.

She concluded by saying this will inspire people to believe the cure is not a dream but is, in fact, reachable.

If you have a story you want to tell, send it to UNILAD via [emailprotected]

A Broadcast Journalism Masters graduate who went on to achieve an NCTJ level 3 Diploma in Journalism, Lucy has done stints at ITV, BBC Inside Out and Key 103. While working as a journalist for UNILAD, Lucy has reported on breaking news stories while also writing features about mental health, cervical screening awareness, and Little Mix (who she is unapologetically obsessed with).

Continue reading here:
Gay Couple Adopt HIV-Positive Child After She Was Rejected By Ten Other Families - UNILAD

Coming Unstuck and Reaching Beyond Ourselves – ALS News Today

Before my husband, Todd, got ALS, we had minor problems, but we were full of hope. We had a small baby so I wasnt getting much sleep, but I knew that things would get better. Todd was sometimes frustrated with his work, but he hoped to be promoted. Our obstacles didnt seem to be insurmountable or permanent.

Challenges were harder once Todd was disabled because there was no hope. I went from sleepless nights for the sake of my children to sleepless nights to help my husband. Todd was no longer discouraged with his work because he couldnt work. He became restless when he had nothing to do. And I became increasingly tethered to home, as I cant leave him for more than a couple of hours.

We were feeling stuck.

Our situation reminds me of a scene from Groundhog Day. Phil Connors, played by Bill Murray, sits down with a couple of guys at a local bar and asks, What would you do if you were stuck in one place, and every day was exactly the same, and nothing you did mattered?

One of the men responds, That about sums it up for me.

Stuck in the small town of Punxsutawney, Pennsylvania, reliving the same day over and over, Phil eventually takes advantage of the time loop to improve himself. He learns to speak French, masters the piano, and becomes skilled at carving ice statues.

Disease and disability shrink our world. We can no longer enjoy the adventures we once did. We dont have control over our futures. But we can do some things.

We have taken advantage of our smaller world to develop new skills. Todd and I have learned the craft of writing, and he helps me to edit my books and articles. Ive become comfortable speaking to groups. Todd created my website, and he has become adept at drawing using his Orin HeadMouse. I make Christmas wreaths from Fraser fir branches and sell them at craft fairs.

In her book Becoming, Michelle Obama writes about how she rose above her working-class upbringing to become a lawyer. Her parents were proud of what the young Michelle Robinson had accomplished. But then after she met Barack, she realized it was one thing to get yourself out of a stuck place, but, it was another thing entirely to try and get the place itself unstuck.

In Groundhog Day, Phil remains stuck even after his self-improvements. He then uses his time loop to reach beyond himself. Every repeated day, he shows up at a restaurant at a particular time to perform the Heimlich maneuver on a choking man. He walks down a street to catch a boy who falls out of a tree. And he tries to save an old man from dying but doesnt succeed.

Sometimes people just die, a nurse tells him. But that doesnt stop Phil from showing compassion. Instead of trying to save him, he spends time with the man, buying him lunch at a local diner.

Phil made Punxsutawney a better place while he was stuck there.

The world is a better place when we reach beyond ourselves.

I admire Steve Gleason for what he has accomplished with Team Gleason the foundation helps people with ALS to access technology to improve their quality of life. Gleason also lobbied for legislation to change the federal policy limiting access to speech-generating devices for people with degenerative diseases.

Most people dont have the financial resources or connections to achieve as much as Gleason has. We can only do our best.

Ive come across bloggers and others on social media who have a wealth of knowledge about navigating ALS. When we have a problem to solve, I look to these folks for resources. Todd and I try to pay it forward. We created a YouTube channel, ALS 411, to share tips and advice about disabled living.

Shortly after Todds diagnosis, I was encouraged by Darcy Wakefields memoir, I Remember Running: The Year I Got Everything I Ever Wantedand ALS. It inspired us to tell our story in our book, Heavy, so that those who read it will know that they are not alone.

Matt Bellina received BrainStorms stem cell treatment under the Right to Try Act. NurOwn is showing positive results in some people with ALS whove been fortunate to get into the trials. Bellina regained his ability to stand up. Now he and others are advocating for the U.S. Food and Drug Administration to approve the experimental therapy immediately so that everyone with ALS can access the treatment.

Its good for our spirits to expand our experiences beyond ourselves, and its even better when we can make a difference in the world.

***

Note: ALS News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of ALS News Today or its parent company, BioNews Services, and are intended to spark discussion about issues pertaining to ALS.

Kristin Neva is an author, blogger, mother of two, and caregiver for her husband, Todd, who has ALS.

View original post here:
Coming Unstuck and Reaching Beyond Ourselves - ALS News Today

Cody Garbrandt looking at a March start for road back to the top – MMA Mania

Following a whirlwind 2016 that saw Cody Garbrandt fight four times and win the UFC bantamweight title, No Love has spent the last three years struggling to stay healthy. He only made it into the cage once a year in 2017, 2018, and 2019, with all three fights ending in KO or TKO. Any hope he had to turn 2019 around ended with a torn tendon in August.

But now Garbrandt sees the light at the end of the tunnel. In an interview with MMA Fighting during his managers Dominance MMA media day, the former 135 pound champ gave a timeline for his return and explained how hyped he was for the year to come.

You guys will see me soon, very soon, Garbrandt said. Almost cleared from my injuries, I tore another tendon, thats two tendons since last March. So hopefully by March or before if my body and mind are feeling up to it. Im excited to get back in, I cannot wait, I miss it.

You really dont get to understand, love, and respect something until its gone, he continued. And its been temporarily gone for me from injuries. Losses I can deal with, but injuries ... it takes a little bit. The healing process and being healthy are two different things. For me to be healthy in 2020, Im excited for that year and what it brings. The challenges and the adversaries that I have. The road back to the top.

For now hell just have to take satisfaction from his various pastimes, which apparently include breeding pitbulls (morally questionable but pretty adorable from what we can tell from the above video) and of course getting tattoos.

In another interview with TMZ, Garbrandt described the 25 hours he spent on the table getting a massive back tattoo done. Further complicating the ordeal was a stem cell injection treatment hed had on his spine just before his tattoo artist called him up.

When he went over the stem cell injection, where they injected from, and man ... woo! he said. That made your asshole pucker up a little bit!

Read the original:
Cody Garbrandt looking at a March start for road back to the top - MMA Mania

Exclusive Growth Report on Animal Stem Cell Therapy Market 2019 Increasing Demand with Leading Key Players: J-ARM,U.S. Stem Cell,Celavet Inc. – Pledge…

The report on Global Animal Stem Cell Therapy Market added by CMR depicts the current & future growth trends of this business besides outlining details pertaining to the myriad geographies that are a part of the regional landscape of Animal Stem Cell Therapy Market. The report further elucidates intricate details regarding the supply and demand analysis, Market share, growth statistics and contributions by leading industry players of Animal Stem Cell Therapy Market.

These Animal Stem Cell Therapy industry trends for short-term, mid-term and long-term during the anticipate phase. Further, the report also covers key players profiling with comprehensive Animal Stem Cell Therapy SWOT analysis, financial facts and key developments of products/service from the past three years.

Get Exclusive Sample PDF Copy of this Report @https://www.crystalmarketresearch.com/report-sample/HC084561

Animal Stem Cell Therapy Market, By Key Players

Check Exclusive Discount on this report @https://www.crystalmarketresearch.com/check-discount/HC084561

Inquiry More to get further questions resolved: https://www.crystalmarketresearch.com/send-an-enquiry/HC084561

Contacts Us:

Judy | 304 South Jones Blvd, Suite 1896

Las Vegas NV 89107

United States

E-mail: sales@crystalmarketresearch.com | Ph: +1-888-213-4282

Excerpt from:
Exclusive Growth Report on Animal Stem Cell Therapy Market 2019 Increasing Demand with Leading Key Players: J-ARM,U.S. Stem Cell,Celavet Inc. - Pledge...

Sarah Ferguson gets candid on using Botox, laser facelifts and stem cell therapy for her feet – Fox News

Sarah Ferguson is telling all on how shes fighting the signs of aging.

Ive had a lot of help to look like this at 60! the ex-wife of Prince Andrew told UKs Daily Mail newspaper on Thursday. Ferguson, nicknamedFergie, revealed shes a fan of non-invasive laser facelifts to keep her features youthful.

Ive started the laser treatment, but its not finished yet, said the proud mom of Princess Eugenie and Princess Beatrice. The collagen needs to rebuild. I hope it will all be done by my birthday.

PRINCESS MADELEINE, PRINCE CARL PHILIP OF SWEDENS CHILDREN LOSE THEIR ROYAL TITLES

The Duchess of York said she used the same treatmentlast year to prepare forPrincess Eugenies royal wedding. People magazine reported the laser lift is meant to work as a natural facelift, stimulating collagen and refinishing skin texture.

Sarah Ferguson, Duchess of York, and Princess Beatrice of York arrive for the royal wedding of Princess Eugenie and Jack Brooksbank at St George's Chapel in Windsor Castle, Windsor, Britain October 12, 2018. (Reuters)

I dont like the frozen look, said Ferguson, who turns the big 6-0 on Oct. 15. Im so animated and I like to be myself. I dont like the thoughts of needles and am very glad if I look well and happy Im really happy to be open about what Ive had done.

ELIZABETH HURLEY MET MEGHAN MARKLE BEFORE PRINCE HARRY DID: 'SHE WAS FANTASTIC'

Ferguson admitted that in the past, she has tried Botox. But these days, Ferguson insisted she relies on more minimally invasive treatments. Shes a fan of mesotherapy, which uses injections of vitamins, minerals and amino acids to boost collagen production. Ferguson said the treatment was the right choice for her after years of sun damage.

I need to repair the damage that was done on the beach when I was a child, she said. Its why I had the mesotherapy, the vitamin cocktail to hydrate and boost the skin.

After that therapy session in 2013, Ferguson said she had a facial thread lift, which involves inserting amesh of medically advanced threads under the skin, lifting the face and smoothing away fine lines.

KATE MIDDLETON'S BROTHER JAMES ANNOUNCES ENGAGEMENT TO FRENCH GIRLFRIEND ALIZEE THEVENET

Sarah Ferguson arrives for the wedding ceremony of Prince Harry and Meghan Markle at St. George's Chapel in Windsor Castle in Windsor, near London, England, Saturday, May 19, 2018. (AP)

ELTON JOHN WRITES QUEEN ELIZABETH SLAPPED HER NEPHEW ACROSS THE FACE IN FRONT OF HIM IN NEW BOOK

Its like garden trellising for sweat peas, said Ferguson. You insert the threads under the skin with a fine needle and they hold everything up. They also encourage collagen production. It takes a couple of months, then the sweat peas blood.

Before I had it done I thought, Oh, this is going to be so painful, but it wasnt bad, Ferguson continued. My skin responded well. I think if you look at photos of me after I had it done, I look much better.

CLICK HERE TO GET THE FOX NEWS APP

And her face wasnt the only thing Ferguson focused on.

According to the outlet, Ferguson traveled to the Bahamas earlier this year to have regenerative stem cell therapy on her feet.

PRINCESS BEATRICE ENGAGED TO EDOARDO MAPELLI MOZZI

Sarah Ferguson is getting candid about how she's fighting the signs of aging. (Reuters)

PRINCESS CHARLOTTE 'LOVES' UNICORNS, DAD PRINCE WILLIAM SAYS

I think my toes were ruined by all the riding I did when I was young, she explained, pointing to her big toe. They shaved the bone here and implanted stem cells, 20 million of them taken from my midriff, into my feet to make new cartilage. It takes about six months to heal but now I can walk in heels!

Read this article:
Sarah Ferguson gets candid on using Botox, laser facelifts and stem cell therapy for her feet - Fox News